In univariate survival analyses including all 338 patients from series 1, strong FOXC2 expression was borderline associated with shorter time to clinical recurrence (p = 0.073), skeletal metastasis (p = 0.081), and cancer specific death (p = 0.069) (see supplementary material, Figure S1 and Table S3). Here, FOXC2 is linked to cancer.